Diroximel fumarate

Phase 3

Biogen Inc. (BIIB)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsing Forms of Multiple Sclerosis

View Full Landscape

Drug Information

Target Indication

Relapsing Forms of Multiple Sclerosis

Clinical Trial

NCT05083923

Last updated: 1/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/15/2021

Vumerity

Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

BIIB

Biogen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

MidazolamPhase 3

Relapsing-Remitting Multiple Sclerosis

SalanersenPhase 3

Muscular Atrophy, Spinal

AvonexPhase 3

Multiple Sclerosis

dimethyl fumaratePhase 3

Relapsing-Remitting Multiple Sclerosis

natalizumabPhase 3

Crohn's Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts